题 目: Aptamer-guided delivery of siRNA to cancer stem cells to overcome chemoresistance
讲座人: Prof. Wei Duan
School of Medicine, Deakin University
时 间: 2014年11月14日(周五) 上午10:30
地 点: 卢嘉锡楼二楼报告厅（202）
欢迎参加!
biwn必赢
2014年11月10日
附：Curriculum Vitae
Name: Wei DUAN Date of Birth: Nov., 1957
Nationality: Australian
Present Appointment: Professor
Contact Information:
Professor Wei Duan
School of Medicine
Deakin University, Waurn Ponds, Victoria, 3217, Australia
Tel:+61 3 5227 1149, Fax:+61 3 5227 2945. E-mail: wduan@deakin.edu.au
Web page: http://www.deakin.edu.au/health/medicine/staff.php?username=wduan
Research Areas:
Aptamer technology, targeted drug delivery, nanomedicine, cancer stem cell, molecular imaging, molecular cell biology of cancer, molecular and nano pharmaceutical science.
Teaching Areas:
Biochemistry, Molecular Cell Biology, Nanomedicine; Medical Biotechnology.
Academic/Professional Qualifications:
Apr. 1988‑‑Aug. 1991
Department of Biochemistry & Molecular Biology,
Faculty of Medicine, The University of Melbourne, Australia
Degree conferred: Ph.D.
Feb. 1978‑‑Dec. 1982 Department of Medicine,
Shanghai University of Traditional Chinese Medicine,
P.R. China
Degree conferred: MBBS.
Career History:
- Lecturer (March, 1986-1May, 1988), Shanghai Medical Staff College, P.R. China
- Research Fellow (April, 1991-December, 1992), University of Melbourne, Australia
- Senior Research Officer (January, 1993-December, 1994), Clinical Neuroscience Centre, Royal Melbourne Hospital, University of Melbourne, Australia
- Research Fellow (January, 1995-April, 1998), University of Melbourne, Australia
- Assistant Professor (May, 1998-April, 2006), National University of Singapore
- Associate Professor (May, 2006-December, 2010 ), Deakin University, Melbourne, Australia
- Professor (January, 2011-- ), Deakin University, Melbourne, Australia
Professional/Consulting Activities:
Faculty Member of Australian National Health & Medical Research Council (NHMRC) Research Translation Faculty, (2012-- )
Vice President, Singapore Society for Biochemistry & Molecular Biology (2000).
Administrative Duties:
- Deputy Chair, Deakin University Laboratory Safety Committee (2010-).
- Member, Deakin University Laboratory Safety Committee (2006-).
- High Degree by Research (Graduate studies) Coordinator for School of Medicine, Deakin University (2008-2009)
- Member, Faculty of Health, Deakin University Human Research Ethics Committee (2008-)
Consulting/Advisory Activities:
- Expert panel member, National Enabling Technologies Strategy Expert Forum, Brisbane, June, 2011 (organised by Department of Industry, Innovation, Science and Research, Australian Government; Council on the Ageing, and Academy of Technology, Science and Engineering)
- External examiner (2012-2015), Faculty of Applied Sciences, AIMST University, Malaysia.
- NHMRC Research Translation Faculty (2012--).
Membership of Editorial Board:
- Drug Design, Development and Therapy, (Impact Factor: 3.026) Associate Editor-in-chief (http://www.dovepress.com/drug-design-development-and-therapy-journal)
- World Journal of Cancer Research (www.aspbs.com/wjcr), Associate Editor
- Medical Sciences (Basel, Switzerland), Member of the Editorial Board
- Aptamers and Synthetic Antibodies, Member of the Editorial Board
- International Journal of Medical Sciences and Biotechnology, Member of the Editorial Board
Honorary Appointment
-Visiting Professor, Sichuan University, China, 2008—present
-Visiting Professor, Dalian Medical University, 2011-present.
Recognition of the Smart Cancer Nanomedicine Programme
Being an Australian leader in developing aptamers against cancer stem cells, Professor Duan is well recognised for his innovative and translational medical research. For example, his work of developing RNA aptamer for cancer diagnosis and treatment was cited by Senator Kim Carr (Minister for Innovation), in his press release on 7 January 2011 as a fine example of the world-class research carried out by Australian leading researchers funded by the Department of Innovation, Industry, Science and Research, Australian Government.
(http://www.innovation.gov.au/science/internationalcollaboration/aisrf/Pages/CaseStudyDetectingCancer.aspx)
Research Awards
1. SMARTGeelong Network, “Researcher of the Year 2011”, sponsored by Gforce.
2. SMARTGeelong Network, " Smart Technology Award”, 2011, sponsored by Geelong Chamber of Commerce.
3. “Researcher of the Year Awards 2008--Biotechnology Award” from Department of Innovation, Industry and Regional Development, State Government of Victoria and Smart Geelong Network, Australia.
Intellectual Properties (Patents):
1. Wei Duan, & Sarah Shigdar,” EpCAM Aptamer for Detection of Cancer Stem Cells,” Australian Provisional Patent Application Filed at IP Australia on August 2, 2012.
Australian Provisional Patent Application 2012903333.
PTC filed on August 2, 2013, PCT/AU2013/000851.
2. Wei Duan, & Sarah Shigdar, “CD133 Aptamers for Cancer Diagnosis”, Australian Provisional Patent Application Filed at IP Australia on August 2, 2012.
Australian Provisional Patent Application 2012903332.
PCT filed on August 2, 2013, PCT/AU201 3/000850.
3. Wei Duan, “Aptamer constructs”, Australian Provisional Patent #2014900347 filed on February 5, 2014;
4. Wei Duan and Jesper Wengel, “Improved aptamers”, Australian Provisional Patent Application #2014900356, filed on February 6, 2014.
